Literature DB >> 7672826

Naturally processed HLA-DR9/DR53 (DRB1*0901/DRB4*0101)-bound peptides.

G Futaki1, H Kobayashi, K Sato, M Taneichi, M Katagiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7672826     DOI： 10.1007/bf00176449

Source DB:  PubMed          Journal:  Immunogenetics        ISSN： 0093-7711            Impact factor:   2.846


× No keyword cloud information.
  21 in total

1.  Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition.

Authors:  J I Krieger; R W Karr; H M Grey; W Y Yu; D O'Sullivan; L Batovsky; Z L Zheng; S M Colón; F C Gaeta; J Sidney
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

2.  Sequence analysis of peptides bound to MHC class II molecules.

Authors:  A Rudensky; P Preston-Hurlburt; S C Hong; A Barlow; C A Janeway
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

3.  Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.

Authors:  R Busch; C M Hill; J D Hayball; J R Lamb; J B Rothbard
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

4.  Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides.

Authors:  A B Vogt; H Kropshofer; H Kalbacher; M Kalbus; H G Rammensee; J E Coligan; R Martin
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

5.  Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.

Authors:  J R Newcomb; P Cresswell
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

6.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.

Authors:  J H Brown; T S Jardetzky; J C Gorga; L J Stern; R G Urban; J L Strominger; D C Wiley
Journal:  Nature       Date:  1993-07-01       Impact factor: 49.962

7.  Promiscuous and allele-specific anchors in HLA-DR-binding peptides.

Authors:  J Hammer; P Valsasnini; K Tolba; D Bolin; J Higelin; B Takacs; F Sinigaglia
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

8.  Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides.

Authors:  A Geluk; K E Van Meijgaarden; A A Janson; J W Drijfhout; R H Meloen; R R De Vries; T H Ottenhoff
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

9.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.

Authors:  R M Chicz; R G Urban; J C Gorga; D A Vignali; W S Lane; J L Strominger
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

10.  Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells.

Authors:  E Mozes; M Dayan; E Zisman; S Brocke; A Licht; I Pecht
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598
View more
  4 in total

1.  Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs.

Authors:  Gema Díaz; Benito Cañas; Jesús Vazquez; César Nombela; Javier Arroyo
Journal:  Immunogenetics       Date:  2004-11-24       Impact factor: 2.846

2.  Analysis of anchor residues in a naturally processed HLA-DR53 ligand.

Authors:  H Kobayashi; T Kokubo; Y Abe; K Sato; S Kimura; N Miyokawa; M Katagiri
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

3.  Epitope analysis of birch pollen allergen in Japanese subjects.

Authors:  Y Abe; S Kimura; T Kokubo; K Mizumoto; M Uehara; M Katagiri
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

4.  Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report.

Authors:  Andrea Aran; Vicente Peg; Rosa Maria Rabanal; Cristina Bernadó; Esther Zamora; Elisa Molina; Yago A Arribas; Joaquín Arribas; José Pérez; Carme Roura-Mir; Montserrat Carrascal; Javier Cortés; Mercè Martí
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.